1. Home
  2. Research and Funding
  3. Current Funding Opportunities
  4. Lead Optimization and Preclinical Development of Therapeutic Candidates for Diseases of Interest to the NIDDK (R41/R42)

Lead Optimization and Preclinical Development of Therapeutic Candidates for Diseases of Interest to the NIDDK (R41/R42)

The goal of this Funding Opportunity Announcement (FOA) is to support lead optimization and preclinical development of new therapies for diseases within the mission of the NIDDK with the STTR program. STTR Phase I projects under this FOA support preliminary steps in the process for lead optimization or preclinical development of therapeutics. STTR Phase II supports lead optimization and preclinical development of lead candidates, and projects must be sufficiently advanced such that an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application to the Food and Drug Administration (FDA) can be submitted by the end of a STTR Phase II or IIB project. Applications are expected to have defined Milestones and Timelines detailing how the project will move forward with identified key Go / No Go decision points.

Key Dates

3/5/2017

Not Applicable

Standard dates apply, by 5:00 PM local time of applicant organization.

*** Note new SBIR/STTR Standard Due Dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.